Curley Gerard F, Laffey John G
Stem Cell Res Ther. 2013 Mar 22;4(2):29. doi: 10.1186/scrt179.
Acute respiratory distress syndrome (ARDS) constitutes a spectrum of increasingly severe acute respiratory failure and is the leading cause of death and disability in the critically ill. There are no therapies for ARDS, and management remains supportive. Cell therapy, particularly with allogeneic mesenchymal stem/stromal cells (MSCs), has emerged as a promising therapeutic strategy for ARDS, favorably modulating the immune response to reduce lung injury, while facilitating lung regeneration and repair. In this issue of the journal, Rojas and colleagues provide us with a rationale to consider autologous bone marrow-mononuclear cells as an alternative to MSCs for this devastating disease.
急性呼吸窘迫综合征（ARDS）是一系列日益严重的急性呼吸衰竭，是危重症患者死亡和致残的主要原因。目前尚无针对ARDS的治疗方法，治疗仍以支持治疗为主。细胞治疗，特别是同种异体间充质干/基质细胞（MSCs），已成为一种有前景的ARDS治疗策略，可通过有利地调节免疫反应来减轻肺损伤，同时促进肺再生和修复。在本期杂志中，罗哈斯及其同事为我们提供了一个理由，即考虑将自体骨髓单个核细胞作为这种毁灭性疾病的MSCs替代物。
